PMID- 34643808
OWN - NLM
STAT- MEDLINE
DCOM- 20220308
LR  - 20220811
IS  - 1436-3771 (Electronic)
IS  - 1432-6981 (Linking)
VI  - 26
IP  - 3
DP  - 2022 Mar
TI  - Treatment of intrabony periodontal defects in controlled diabetic patients with 
      an enamel matrix derivative: a split-mouth randomized clinical trial.
PG  - 2479-2489
LID - 10.1007/s00784-021-04215-w [doi]
AB  - OBJECTIVE: This split-mouth randomized controlled trial aimed to evaluate the 
      effect of enamel matrix derivative (EMD) associated with a simplified papilla 
      preservation flap (SPPF) compared to SPPF alone in the surgical treatment of 
      intrabony defects (ID) in type 2 diabetic mellitus (T2DM) patients. MATERIAL AND 
      METHODS: Thirteen patients with controlled T2DM presenting with ID in at least 
      two quadrants were included. In each patient, the test site (TS) was treated with 
      SPPF plus EMD, whereas the control site (CS) was treated only with SPPF. Prior to 
      surgery and at 6 months after intervention, the following parameters were 
      evaluated: clinical attachment level (CAL), probing pocket depth (PPD), and 
      gingival recession (GR). RESULTS: The TS and CS demonstrated a mean CAL gain of 
      3.31 +/- 0.96 mm and 1.61 +/- 1.12 mm, and a PPD reduction from 8.15 +/- 0.98 to 
      3.00 +/- 0.57 mm and 7.53 +/- 0.96 to 4.69 +/- 0.63 mm after 6 months, respectively. In 
      both sites, the mean CAL gain and PPD reduction improved significantly after 
      6 months compared to baseline; however, the improvement was higher in the TS 
      (p < 0.001). CONCLUSIONS: Both surgical procedures presented with clinical 
      improvements in controlled T2DM patients. However, the additional use of EMD 
      showed enhanced clinical results after 6 months with regard to CAL gain and PPD 
      reduction. CLINICAL RELEVANCE: This study showed a better PPD reduction and CAL 
      gain when an EMD was applied in addition to SPPF. Therefore, EMD may be used to 
      enhance clinical outcomes in periodontal ID of controlled T2DM patients.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Cimoes, Renata
AU  - Cimoes R
AUID- ORCID: 0000-0003-3673-8739
AD  - Department of Prosthesis and Oral Facial Surgery, Federal University of 
      Pernambuco, Recife, Pernambuco, Brazil. renata.silveira@ufpe.br.
FAU - Santiago, Leogenes M
AU  - Santiago LM
AD  - Faculty of Dentistry of Caruaru, Caruaru, Pernambuco, Brazil.
FAU - de Franca Caldas Junior, Arnaldo
AU  - de Franca Caldas Junior A
AD  - Department of Clinics and Preventive Dentistry, Federal University of Pernambuco, 
      Recife, Pernambuco, Brazil.
FAU - de Carvalho Farias Vajgel, Bruna
AU  - de Carvalho Farias Vajgel B
AD  - Department of Prosthesis and Oral Facial Surgery, Federal University of 
      Pernambuco, Recife, Pernambuco, Brazil.
FAU - Perussolo, Jeniffer
AU  - Perussolo J
AD  - Centre for Oral Immunobiology & Regenerative Medicine and Centre for Oral 
      Clinical Research, Institute of Dentistry, Barts and The London School of 
      Medicine and Dentistry, Queen Mary University of London (QMUL), London, UK.
FAU - Donos, Nikolaos
AU  - Donos N
AD  - Centre for Oral Immunobiology & Regenerative Medicine and Centre for Oral 
      Clinical Research, Institute of Dentistry, Barts and The London School of 
      Medicine and Dentistry, Queen Mary University of London (QMUL), London, UK.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20211013
PL  - Germany
TA  - Clin Oral Investig
JT  - Clinical oral investigations
JID - 9707115
RN  - 0 (Dental Enamel Proteins)
MH  - *Alveolar Bone Loss/surgery
MH  - *Dental Enamel Proteins/therapeutic use
MH  - *Diabetes Mellitus
MH  - Follow-Up Studies
MH  - *Gingival Recession/drug therapy/surgery
MH  - Guided Tissue Regeneration, Periodontal/methods
MH  - Humans
MH  - Periodontal Attachment Loss/drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - Enamel matrix derivate
OT  - Enamel matrix protein
OT  - Intrabony defects
OT  - Periodontal diseases/therapy
OT  - Periodontal regeneration
EDAT- 2021/10/14 06:00
MHDA- 2022/03/09 06:00
CRDT- 2021/10/13 12:27
PHST- 2021/06/03 00:00 [received]
PHST- 2021/09/26 00:00 [accepted]
PHST- 2021/10/14 06:00 [pubmed]
PHST- 2022/03/09 06:00 [medline]
PHST- 2021/10/13 12:27 [entrez]
AID - 10.1007/s00784-021-04215-w [pii]
AID - 10.1007/s00784-021-04215-w [doi]
PST - ppublish
SO  - Clin Oral Investig. 2022 Mar;26(3):2479-2489. doi: 10.1007/s00784-021-04215-w. 
      Epub 2021 Oct 13.